Clinical Trial 44163

Santa Monica, CA 90403


This is a Phase 2 clinical research study of investigational drug XT-150 in participants experiencing moderate to severe pain due to osteoarthritis of the knee.

XT-150 is a plasmid DNA that will be injected into the intra-articular space of the affected knee, and has been shown to reduce inflammation through cytokine IL-10. The possible benefits of this clinical study include increased mobility following a single dose, reduction in requirement for pain medications/therapies, and reduction in pain symptoms.

If you are interested in this study, you will be sent an online pre-screening questionnaire to further determine your eligibility. If you meet all the study criteria and consent to take part in the study, you will be coming to our clinical site for monthly visits over the course of 1 year.


  • Be between the ages of 45 and 85
  • Have a clinical diagnosis of Grade 2 or 3 knee osteoarthritis
  • No scheduled partial or complete knee replacement within 6 months
  • No history of rheumatoid arthritis or other inflammatory disease
  • No current treatment with systemic immunosuppressants, steroids, antibiotics, or antivirals

Qualified Participants May Receive:

Qualified participants may receive:

This study involves a total of 15 visits at our site including screening, injection day, and monthly follow-ups. There is no cost to the participant for the investigational product, office visits, examinations, and laboratory tests that are required solely by the study. Stipends may be allocated to assist the participants in the study.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.